Poster Presentations and finally severe refractory disease needed surgery (patients treated with immunosupressants, biologic treatment and requiring surgery, score 6). Results: Of the 2854 patients, representing about 50% of the calculated number of Portuguese patients with CD, 1245 (44%) were male and 1609 (56%) female. The median follow-up years after diagnosis was 6 (p25-2; p75-11). 185 patients had five years of disease, 1403 at least five years, 685 at least 10 years, 326 at least 15 years, 178 at least 20 years and 19 at least 25 years of disease. After five years of disease 65% of patients took at least a steroids course and 86% after 20 years. 33% of patients were doing immunosuppressants at five years and this proportion increased to achieved 51% at ten years, remaining constant thereafter. Most of the patients needed at least one intestinal resection. At five years the first surgery rate was 23% and at 20 years was 71%. Twenty percent of patients were taking anti-TNF agents. A minority of patients (<5%) persisted without steroids, immunosupression or surgery and 20% remained during any given year without immunnosupression and surgery. Most of patients needed immunosupression (40%), and a number significant of patients were submitted to surgery without immunosupression (20%). Patients with five years of disease the mean severity was 2 (interquartile range 1-4), for those with 15 years was 3 (2-5) and in patients with 25 years was 5 (3-5). In behaviour groups in nonstenosing-nonpenetrating the mean severity was 2 (1-3), in stenosing was 4 (2-5) and in penetrating was 5 (3-5). Background: Threonine contributing as one of the majority amino acids of the mucins protein and inflammatory bowel disease (IBD) associated with threonine decreased in mucins proteins. Moreover, there is suggest that mucus gel layer less enriched threonine has altered integrity and protective function. Aim: Evaluate threonine derivative, as modified threonin-threonine (dithreonine), efficacy at the dextran sulfate sodium (DSS) model of experimental mouse colitis. Material and methods: Acute colitis was induced in Swiss-Webster mice by 7 days of oral 2,5% DSS with animals sacrificed daily (DSS group, 8 mouse in each day by 7 days, total 56). In experimental di-threonine groups (DSS+Di-th): di-threonine started to enter oral in dose 0,5 g BID on the third day from the beginning of an DSS induction colitis, with animals sacrificed daily (8 mouse in each day by 7 days, total 56). In each experimental group, the entire colons were examined macroscopically (colon length-CL) and histologically (histological activity index-HAI) and with clinical symptoms (animals weight-AW, blood in stool, protein content in serum, hematology parameters and colitis activity index -CAI). Results: In DSS groups was found: 1) acute clinical symptoms (diarrhea and/or grossly bloody stool) were associated with the presence of erosions and inflammation in colon. The earliest histological changes, which predated clinical colitis, was on day 3; 2) animals loose weight at day 7 on 6,4% (CI 95%=3,7-9,0); 3) LC was at day 3 -8,5 (CI95%=6,4-10,6) and at day 7 -6,2 (CI95%=5,6-6,7); CAI was at day 7 -1,9 (CI95%=1,7-2,1), HAI at day 7 -3,0 (CI95%=2,5-3,5). In DSS+Di-th groups was found: 1) animals had weight increase at day 7 on 2,3% (CI95%= -0,9 -+5,5), p significant vs DSS= 0,02; 2) LC was at day 3 -7,9 (CI95%=5,5-10,3) and at day 7 -7,8 (CI95%=7,1-8,4, p significant vs DSS= 0,04); CAI was at day 7 -0,25 (CI95%=0-0,64, p significant vs DSS= 0,01), HAI at day 7 -2,3 (CI95%=1,6-3,6, not significant vs DSS). Serum protein at 7 day (DSS+ Di-th vs DSS: 60,0 (CI95%= 55,6-62,3) vs 53,6 (CI95%=51,2-56,1) at p=0,008).
Conclusions

Conclusion:
This study first time clearly demonstrated that threonine' s dipeptide has positive efficacy at the experimental induced colitis and it may be very promising new medication for IBD.
P063 DO FREQUENTLY AND CONCOMITANTLY USED DRUGS IN IBD PATIENTS AFFECT THE EXPRESSION OF GR MRNA?
E. Bultman, R. Quax, J. Koper, S. Lamberts, E. Kuipers, R. Feelders, J. van der Woude. Erasmus MC, Rotterdam, The Netherlands Background and aim: Glucocorticoids (GCs) are effective as induction therapy in inflammatory bowel disease (IBD) patients. Known is that there is significant inter individual variation in the response to GCs, partially due to different expression levels of the splice variants of the GC Receptor (GR) mRNA. Few data are available on the interaction of drugs on the expression of splice variants. Three 3' -splice variants of the GR have been described: GR-α is the major, biologically active form; GR-β has been reported to have dominant negative effects on the function of GR-α, while GR-P stimulates GR-α action. In IBD frequently drugs are prescribed concomitantly. Therefore we were interested in the influence of methotrexate (MTX), sulfasalazine (SSZ) and prednisolone (PRED) on the expression of the splice variants of GR mRNA. Materials and Methods: Mononuclear leukocytes, obtained from buffy coats of healthy blood donors, were incubated with PRED (10 -8 M, 10 -7 M, 10 -6 M), MTX (10 -8 M, 10 -7 M, 10 -6 M) and SSZ (7,5µM, 15µM, 30µM) during 4, 24, 48 and 72 h. Concentrations reflect steady state concentrations of these drugs in IBD patients. Levels of GR mRNA were measured using quantitative rt-PCR. Statistical analysis was performed by one-way ANOVA with a Newman-Keuls post test. P-values <0.05 were considered significant. Results: GR-α mRNA decreased significantly in time for each concentration (MTX p<0.05, SSZ p< 0.003, PRED p<0.006). The decrease of GR-α mRNA upon incubation with MTX was equal to the decrease in the controls. For MTX and PRED, there was no difference between concentrations for each period of incubation, however PRED showed a trend to decrease dose dependently (p values PRED: 4h 0.11; 24h 0.12; 48h 0.26; 72h 0.59). For SSZ a reduction was seen at 4 hours of incubation for concentrations 15µM and 30µM (p=0.002) and an increase at 24 hours at a concentration of 7,5µM (p=0.007). For GR-β mRNA a trend to decrease in time could be seen, however due to variation, this was not significant. There was no difference between concentrations. Conclusion: MTX did not influence GR mRNA expression. SSZ however, showed an decrease of GR-α mRNA at 4 hours incubation at high concentration and an increase of GR-α mRNA at 24 hours of incubation at low concentration. PRED shows a trend to dosage-and time-dependent reduction of the level of the GR-α mRNA. These results suggest an interaction of concomitantly used drugs on the GR mRNA isoform expression, however more studies are needed. This study was sponsored by an unrestricted grant from UCB, the Netherlands.
